Radiation Therapy after Neoadjuvant Systemic Therapy: The Role of Regional Nodal Irradiation

The significance of radiation therapy following neoadjuvant systemic therapy is a topic of ongoing discussion, specifically concerning regional nodal irradiation in patients achieving a complete response. Recent data from the B51 trial presented at the last San Antonio Breast Cancer Symposium shed light on this issue for various subtypes: her2-positive, hormone receptor-positive (HER2+, HR+), and triple negative breast cancer (TNBC).

B51 Trial Insights:

The initial analysis of the B51 trial didn’t show any impact of post-complete response radiation therapy on node irradiation in this population. However, it’s important to note that subgroup analyses are still awaited to determine which specific subgroups may benefit from radiotherapy in this setting.

Summary:

The discussion surrounding radiation therapy after complete response to neoadjuvant systemic therapy is a topic of ongoing interest, with recent data from the B51 trial providing initial insights into the impact of this treatment in various subtypes of breast cancer. Although the first analysis didn’t reveal any benefits for patients who received post-complete response radiation therapy on node irradiation, awaited subgroup analyses are expected to shed more light on which specific patient groups may benefit from this approach.